Last reviewed · How we verify
KPI-121
At a glance
| Generic name | KPI-121 |
|---|---|
| Also known as | KPI-121 0.25% Ophthalmic Suspension, Loteprednol etabonate |
| Sponsor | Kala Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of KPI-121 in Subjects With DED (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (PHASE2)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE2)
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain (PHASE3)
- Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KPI-121 CI brief — competitive landscape report
- KPI-121 updates RSS · CI watch RSS
- Kala Pharmaceuticals, Inc. portfolio CI